A Phase 3 interventional study of Ranibizumab injection 0.3 mg and Ranibizumab injection 0.5 mg in Macular Edema and Retinal Vein Occlusion, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 4th largest by enrollment, is one of 9 that started in 2007, is one of 25 in phase 3, and was the 8th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 397 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2007, is one of 14 in phase 3, and was the 3rd registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO); 397 patients with BRVO were enrolled at 93 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Inclusion Criterion (Study Eye):
Exclusion Criteria:
Ocular Exclusion Criteria (Study Eye):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sham injection
Drug: Ranibizumab injection 0.3 mg
Drug: Ranibizumab injection 0.5 mg
Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Also known as: Lucentis
Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Also known as: Lucentis
Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months
BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.
Time frame: Baseline and 6 months
Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline
BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.
Time frame: Baseline and 6 months
Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline
BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters. The percentage of subjects who lost \<15 letters will be greater than the percentage of subjects who "gained \>=15 letters" as "losing \<15 letters" includes both those who gained \>=15 letters and those who were "stable" (i.e. lost between 1 and 14 letters, had no change, or gained between 1 and 14 letters).
Time frame: Baseline and 6 months
Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6
A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.
Time frame: 6 months
Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6
A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.
Time frame: Baseline and 6 months
Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6
The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.
Time frame: Baseline and 6 months
Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6
The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.
Time frame: Baseline and 6 months
Please note that although the table below is titled "Overall Study," the completion rates are for the 6-month Treatment Period only (i.e., does not include the 6-month Observation Period data).
| Milestone | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Started | 132 | 134 | 131 |
| Received drug (safety population) | 131 | 134 | 130 |
| Completed | 123 | 128 | 125 |
| Not completed | 9 | 6 | 6 |
BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.
| Units on a scale | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Baseline | 54.7 ± 12.2 | 56.0 ± 12.1 | 53.0 ± 12.5 |
| Change from Baseline at Month 6 | 7.3 ± 13.0 | 16.6 ± 11.0 | 18.3 ± 13.2 |
BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.
| Percentage of participants | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline | 28.8 (21.1 to 36.5) | 55.2 (46.8 to 63.6) | 61.1 (52.7 to 69.4) |
BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters. The percentage of subjects who lost \<15 letters will be greater than the percentage of subjects who "gained \>=15 letters" as "losing \<15 letters" includes both those who gained \>=15 letters and those who were "stable" (i.e. lost between 1 and 14 letters, had no change, or gained between 1 and 14 letters).
| Percentage of participants | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline | 95.5 (90.5 to 98.0) | 100 (97.4 to 100) | 98.5 (94.6 to 99.7) |
A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.
| Percentage of participants | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6 | 45.5 (37.0 to 53.9) | 91.0 (86.2 to 95.9) | 84.7 (78.6 to 90.9) |
A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.
| μm | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Baseline | 488.0 ± 192.2 | 522.1 ± 201.9 | 551.7 ± 223.5 |
| Mean Absolute Change from Baseline at Month 6 | -157.7 ± 224.2 | -337.3 ± 224.4 | -345.2 ± 238.2 |
The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.
| Points on the NEI VFQ-25 subscale | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Baseline | 69.6 ± 20.2 | 67.9 ± 22.1 | 69.4 ± 20.5 |
| Change from baseline at Month 6 | 7.3 ± 15.3 | 12.1 ± 17.3 | 13.7 ± 18.0 |
The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.
| Points on the NEI-VFQ-25 subscale | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Baseline | 76.4 ± 20.6 | 76.0 ± 20.5 | 76.7 ± 18.1 |
| Mean Change from Baseline at Month 6 | 6.3 ± 15.0 | 10.3 ± 17.2 | 11.3 ± 16.6 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sham Injection | — | 6/131 (4.6%) | 115/131 (87.8%) |
| Ranibizumab Injection 0.3 mg | — | 14/134 (10.4%) | 125/134 (93.3%) |
| Ranibizumab Injection 0.5 mg | — | 14/130 (10.8%) | 115/130 (88.5%) |
| Event | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/131 | 2/134 | 0/130 |
| HypertensionVascular disorders | 0/131 | 2/134 | 0/130 |
| Acute Myocardial InfarctionCardiac disorders | 0/131 | 0/134 | 1/130 |
| Angina UnstableCardiac disorders | 0/131 | 0/134 | 1/130 |
| BradycardiaCardiac disorders | 0/131 | 0/134 | 1/130 |
| Gaze PalsyEye disorders | 0/131 | 0/134 | 1/130 |
| Retinal Vein OcclusionEye disorders | 0/131 | 0/134 | 1/130 |
| Colonic PolypGastrointestinal disorders | 0/131 | 0/134 | 1/130 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/131 | 1/134 | 1/130 |
| Intestinal PerforationGastrointestinal disorders | 0/131 | 0/134 | 1/130 |
| Event | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg |
|---|---|---|---|
| Conjunctival HemorrhageEye disorders | 55/131 | 80/134 | 71/130 |
| Retinal ExudatesEye disorders | 20/131 | 37/134 | 32/130 |
| Eye PainEye disorders | 19/131 | 33/134 | 21/130 |
| Retinal HemorrhageEye disorders | 18/131 | 23/134 | 23/130 |
| Ocular Vascular DisorderEye disorders | 16/131 | 21/134 | 10/130 |
| MyodesopsiaEye disorders | 2/131 | 17/134 | 6/130 |
| MaculopathyEye disorders | 11/131 | 16/134 | 16/130 |
| Retinal DepigmentationEye disorders | 6/131 | 6/134 | 15/130 |
| Retinal Vascular DisorderEye disorders | 9/131 | 10/134 | 15/130 |
| Ocular HyperemiaEye disorders | 6/131 | 13/134 | 8/130 |
| Age, Continuous(years) | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg | Total |
|---|---|---|---|---|
| Mean | 65.2 ± 12.7 | 66.6 ± 11.2 | 67.5 ± 11.8 | 66.4 ± 11.9 |
| Age, Customized(participants) | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg | Total |
|---|---|---|---|---|
| < 45 years | 8 | 5 | 4 | 17 |
| 45 to < 65 years | 59 | 51 | 51 | 161 |
| 65 to < 85 years | 60 | 74 | 69 | 203 |
| ≥ 85 years | 5 | 4 | 7 | 16 |
| Sex: Female, Male(Participants) | Sham Injection | Ranibizumab Injection 0.3 mg | Ranibizumab Injection 0.5 mg | Total |
|---|---|---|---|---|
| Female | 58 | 67 | 60 | 185 |
| Male | 74 | 67 | 71 | 212 |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of May 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 9 months after primary completion. A results delay was requested in May 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab